What is claimed is:
1. A method of treating a human afflicted by or susceptible to an allergic disorder while avoiding the concomitant liability of adverse effects associated with the administration of astemizole, comprising administering to said human afflicted by or susceptible to an allergic disorder an amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said allergic disorder, but insufficient to cause said adverse effects.
2. The method of claim 1 wherein the amount of metabolic derivative administered is from about 1 mg to about 200 mg per day.
3. The method of claim 2 wherein the amount of metabolic derivative administered is from about 1 mg to about 50 mg per day.
4. The method of claim 1 wherein the amount of said metabolic derivative or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
5. A composition adapted for the treatment of a human having an allergic disorder, comprising an amount of a metabolic derivative of astemizole selected from the group consisting of desmthylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said allergic disorder, but insufficient to cause adverse effects associated with the administration of astemizole.
6. The composition of claim 5, further comprising a pharmaceutically acceptable carrier.
7. A method of treating a human afflicted with asthma while avoiding the concomitant liability of adverse effects associated with the administration of astemizole, comprising administering to said human afflicted with asthma an amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said asthma, but insufficient to cause said adverse effects.
8. The method of claim 7 wherein the amount of metabolic derivative administered is from about 1 mg to about 200 mg per day.
9. The method of claim 8 wherein the amount of metabolic derivative administered is from about 1 mg to about 50 mg per day.
10. The method of claim 7 wherein the amount of said metabolic derivative or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
11. A composition adapted for the treatment of asthma in a human, comprising an amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said asthma, but insufficient to cause adverse effects associated with the administration of astemizole.
12. The composition of claim 11, further comprising a pharmaceutically acceptable carrier.
13. A method of treating motion sickness or vertigo in a human while avoiding the concomitant liability of adverse effects associated with the administration of astemizole, comprising administering to said human an amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole, norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said motion sickness or vertigo, but insufficient to cause said adverse effects.
14. The method of claim 13 wherein the amount of metabolic derivative administered is from about 1 mg to about 200 mg per day.
15. The method of claim 14 wherein the amount of metabolic derivative administered is from about 1 mg to about 50 mg per day.
16. The method of claim 13 wherein the amount of said metabolic derivative or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
17. A composition adapted for treating motion sickness or vertigo in a human which comprises an amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said motion sickness or vertigo, but insufficient to cause adverse effects associated with the administration of astemizole.
18. The composition of claim 17, further comprising a pharmaceutically acceptable carrier.
19. A method for treating retinopathy or other small vessel diseases associated with diabetes mellitus in a human while avoiding the concomitant liability of adverse effects associated with the administration of astemizole, comprising administering to said human an amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said retinopathy or other small vessel diseases associated with diabetes mellitus, but insufficient to cause said adverse effects.
20. The method of claim 19 wherein the amount of metabolic derivative administered is from about 1 mg to about 200 mg per day.
21. The method of claim 20 wherein the amount of metabolic derivative administered is from about 1 mg to about 50 mg per day.
22. The method of claim 19 wherein the amount of said metabolic derivative or pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.
23. A composition adapted for treating retinopathy or other small vessel diseases associated with diabetes mellitus in a human, comprising an amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, said amount being sufficient to treat said retinopathy or other small vessel diseases associated with diabetes mellitus, but insufficient to cause adverse effects associated with the administration of astemizole.
24. The composition of claim 23, further comprising a pharmaceutically acceptable carrier.
25. A pharmaceutical composition useful in the treatment of cough, cold, cold-like and flu symptoms and the discomfort, pain, fever and general malaise associated therewith, in a human, said composition comprising (i) a therapeutically effective amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole, and norastemizole, or pharmaceutically acceptable salts thereof, and (ii) a therapeutically effective amount of a non-steroidal anti-inflammatory agent or non-narcotic analgesic.
26. The composition of claim 25 comprising from about 1 mg to about 50 mg of said metabolic derivative and from about 25 mg to about 600 mg of said anti-inflammatory or analgesic.
27. The composition of claim 25, further comprising a pharmaceutically acceptable carrier.
28. A pharmaceutical composition useful in the treatment of cough, cold, cold-like and flu symptoms and the discomfort, pain, fever and general malaise associated therewith, in a human, said composition comprising (i) a therapeutically effective amount of a metabolic derivative of astemizole selected from the group consisting of desmethylastemizole, 6-hydroxydesmethylastemizole and norastemizole, or pharmaceutically acceptable salts thereof, and (ii) a therapeutically effective amount of a decongestant.
29. The composition of claim 28 comprising from about 1 mg to about 50 mg of said metabolic derivative and from about 5 mg to about 150 mg of said decongestant.
30. The composition of claim 28, further comprising a pharmaceutically acceptable carrier.
31. A method for the treatment of allergic reaction, cough, cold, cold-like, and flu syptoms and the discomfort, pain, fever, and general malaise associated therewith, in a human in need of such treatment comprising administering to said human a composition according to claim 25.
32. The method of claim 31 wherein said allergic reaction is rhinitis.
33. A method for the treatment of allergic reaction, cough, cold, cold-like, and flu symptoms and the discomfort, pain, fever, and general malaise associated therewith, in a human in need of such treatment, comprising administering to said human a composition according to claim 28.
34. The method of claim 33 wherein said allergic reaction is rhinitis.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-14. (Canceled)
15. A casket shell comprising:
a box made of a fiberboard material and including longitudinally spaced-apart end walls, transversely spaced-apart side walls, and a bottom wall extending between the side and end walls, the side walls cooperating with the end walls and the bottom wall to define an interior region of the casket shell, the side walls and end walls each having a top edge,
a lower perimetral frame abutting a bottom portion of the box to reinforce the bottom portion of the box, and
an upper perimetral frame including a first portion covering the top edges of the side and end walls and a second portion abutting an upper portion of the box to reinforce the upper portion of the box.
16. The casket shell of claim 15, wherein the lower perimetral frame surrounds the lower portion of the box and the second portion of the upper perimetral frame surrounds the upper portion of the box.
17. The casket shell of claim 15, wherein the lower perimetral frame includes a downwardly facing surface that is substantially coplanar with a bottom surface of the bottom wall of the box, an upwardly facing surface vertically spaced apart from the downwardly facing surface, and an inwardly facing surface extending between the upwardly facing surface and the downwardly facing surface, the inwardly facing surface abutting the side and end walls of the box.
18. The casket shell of claim 15, further comprising a memorial tube configured to receive records regarding a deceased person, one of the end walls of the box being formed to include a memorial tube-receiving notch, the upper perimetral frame being formed to include a memorial-tube receiving aperture, and the memorial tube being received in the memorial tube-receiving notch and the memorial tube-receiving aperture.
19. The casket shell of claim 15, wherein the first portion of the upper perimetral frame abuts the top edges of the side and end walls.
20. A blank for forming a casket shell of a casket, the blank comprising:
a bottom panel,
a pair of side panels appended to the bottom panel, and
a plurality of end flaps appended to the bottom panel and the side panels, a first of the end flaps being formed to include a first notch and a second of the panels, a first of the end flaps being formed to include a first notch and a second of the end flaps being formed to include a second notch, the blank being foldable to form the casket shell so that the first notch cooperates with the second notch to define an opening for receiving an object.
21. The blank of claim 20, wherein the first notch includes a first open end at an edge of the first end flap, the second notch includes a second open end at an edge of the second end flap, and the first open end aligns with the second open end when the blank is folded to form the casket shell.
22. The blank of claim 20, wherein the first and second notches are sized to receive a capsule containing information about a deceased.
23. The blank of claim 20, wherein the first and second notches are configured so that a capsule extending from a frame member coupled to the blank and containing information about a deceased is received therein.
24. A casket comprising:
a casket shell having longitudinally spaced-apart first and second end walls, transversely spaced-apart side walls, and a bottom wall cooperating with the end walls and side walls to define an interior region of the casket,
a body support positioned to lie in the interior region of the casket and configured to support the body of a deceased, the body support having longitudinally spaced-apart first and second ends, and
an end insert panel positioned to lie in the interior region of the cakset, the end insert being fastened to the first end wall and coupled to the body support.
25. The casket of claim 24, wherein at least a portion of the casket shell is made of a fiberboard material and the end insert panel is made of a material stronger than the fiberboard material.
26. The casket of claim 24, wherein the first end wall of the casket shell includes an interior surface and the end insert panel substantially covers the interior surface of the first end wall.
27. The casket of claim 24, wherein the casket shell includes a box and an upper perimetral frame coupled to the box and the tilting mechanism is coupled to upper perimetral frame.